Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 2, 2013, Pages 1057-1060

  Xu, Yun Zhao ^a   Xi, Qing Hua ^a   Ge, Wen Liang ^a   Zhang, Xiao Qian ^a  

^a The 1st People's Hospital of Nan Tong   (China)

Author keywords

Epithelial ovarian cancer; Mir 21; Prognosis; Real time reverse transcriptase PCR; Tumor stage

Indexed keywords

MICRORNA; MIRN21 MICRORNA, HUMAN; TUMOR MARKER;

ARTICLE; BLOOD; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MIDDLE AGED; MORTALITY; NEOPLASM; OVARY TUMOR; PROGNOSIS; SURVIVAL; UPREGULATION;

FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84877658010     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.2.1057     Document Type: Article

References (38)

1. Asaga S, Kuo C, Nguyen T, et al (2011). Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem, 57, 84-91.
2. Bartel DP (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-97.
3. Brennecke J, Stark A, Russell RB, Cohen SM (2005). Principles of microRNA-target recognition. PLoS Biol, 3, e85.
4. Calin GA, Sevignani C, Dumitru CD, et al (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A, 101, 2999-3004.
5. Chan JA, Krichevsky AM, Kosik KS (2005). MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res, 65, 6029-33.
6. Chan SH, Wu CW, Li AF, et al (2008). miR-21 microRNA expression in human gastric carcinomas and its clinical association. Anticancer Res, 28, 907-11.
7. Corney DC, Hwang CI, Matoso A, et al (2010). Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res, 16, 1119-28.
8. Davidson-Moncada J, Papavasiliou FN, Tam W (2010). MicroRNAs of the immune system: roles in inflammation and cancer. Ann N Y Acad Sci, 1183, 183-94.
9. Feber A, Xi L, Luketich JD, et al (2008). MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg, 135, 255-60; discussion 60.
10. Friedman RC, Farh KK, Burge CB, Bartel DP (2009). Most mammalian mRNAs are conserved targets of microRNAs. Genome Res, 19, 92-105.
11. Hiyoshi Y, Kamohara H, Karashima R, et al (2009). MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res, 15, 1915-22.
12. Iorio MV, Ferracin M, Liu CG, et al (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 65, 7065-70.
13. Iorio MV, Visone R, Di Leva G, et al (2007). MicroRNA signatures in human ovarian cancer. Cancer Res, 67, 8699- 707.
14. Krek A, Grun D, Poy MN, et al (2005). Combinatorial microRNA target predictions. Nat Genet, 37, 495-500.
15. Kuehbacher A, Urbich C, and Dimmeler S (2008). Targeting microRNA expression to regulate angiogenesis. Trends Pharmacol Sci, 29, 12-5.
16. Kurashige J, Kamohara H, Watanabe M, et al (2012). Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma. J Surg Oncol, 106, 188-92.
17. Lawrie CH, Gal S, Dunlop HM, et al (2008). Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol, 141, 672-5.
18. Liu ZY, Zhang GL, Wang MM, et al (2011). MicroRNA-663 targets TGFB1 and regulates lung cancer proliferation. Asian Pac J Cancer Prev, 12, 2819-23.
19. Malpica A, Deavers MT, Lu K, et al (2004). Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol, 28, 496-504.
20. Markou A, Tsaroucha EG, Kaklamanis L, et al (2008). Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem, 54, 1696-704.
21. Meng F, Henson R, Lang M, et al (2006). Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology, 130, 2113-29.
22. Meng F, Henson R, Wehbe-Janek H, et al (2007). MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 133, 647-58.
23. Roldo C, Missiaglia E, Hagan JP, et al (2006). MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol, 24, 4677-84.
24. Sabatel C, Malvaux L, Bovy N, et al (2011). MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells. PLoS One, 6, e16979.
25. Si ML, Zhu S, Wu H, et al (2007). miR-21-mediated tumor growth. Oncogene, 26, 2799-803.
26. Slaby O, Svoboda M, Fabian P, et al (2007). Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology (Williston Park), 72, 397-402.
27. Song T, Xia W, Shao N, et al (2010). Differential miRNA expression profiles in bladder urothelial carcinomas. Asian Pac J Cancer Prev, 11, 905-11.
28. Tran N, McLean T, Zhang X, et al (2007). MicroRNA expression profiles in head and neck cancer cell lines. Biochem Biophys Res Commun, 358, 12-7.
29. Tsujiura M, Ichikawa D, Komatsu S, et al (2010). Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer, 102, 1174-9.
30. Volinia S, Calin GA, Liu CG, et al (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A, 103, 2257-61.
31. Wang P, Zhuang L, Zhang J, et al (2012). The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL. Mol Oncol, pii: S1574- 7891(12)00109-3.
32. Wang ZX, Bian HB, Wang JR, et al (2011). Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer. J Surg Oncol, 104, 847-51.
33. Xu J, Wu C, Che X, et al (2011). Circulating microRNAs, miR- 21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog, 50, 136-42.
34. Yang H, Kong W, He L, et al (2008). MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res, 68, 425-33.
35. Zhang B, Cai FF, Zhong XY (2011a). An overview of biomarkers for the ovarian cancer diagnosis. Eur J Obstet Gynecol Reprod Biol, 158, 119-23.
36. Zhang HL, Yang LF, Zhu Y, et al (2011b). Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate, 71, 326-31.
37. Zhang Z, Li Z, Gao C, et al (2008). miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest, 88, 1358-66.
38. Zhou L, Zhao YP, Liu WJ, et al (2012). Circulating microRNAs in cancer: diagnostic and prognostic significance. Expert Rev Anticancer Ther, 12, 283-8.